NASDAQ · NVCT
Nuvectis Pharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NVCT: Nov 3, 2026
Nuvectis Pharma, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.22. The reported EPS for the same quarter last year was $-0.44.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.22 | $-0.21 | $-0.23 | 2 |
| Dec 2026 | $-0.23 | $-0.20 | $-0.25 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Oct 26, 1:04 PM EDTNuvectis' NXP200 Shows Complete Responses In BRAF-Mutated Recurrent Gliomas(RTTNews) – Nuvectis Pharma, Inc. (NVCT) reported positive expanded Phase 1b data for NXP200, an investigational second-generation BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated gliomas at the 2026 European Society for Medical Oncology (ESMO) Congress
- Zacks · Aug 19, 11:33 AM EDTNuvectis Stock Surges Around 97% in 3 Months: Here's WhyNVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
- Zacks · Jul 29, 9:55 AM EDTWall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should KnowThe mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- RTTNews · Jul 23, 12:01 PM EDTNuvectis' Partner Haisco Wins NMPA Marketing Approval For Ciprocopan In Rare Blood Disorder(RTTNews) – Nuvectis Pharma, Inc. (NVCT), a clinical-stage biopharmaceutical company, announced on Thursday the receipt of marketing approval from the Chinese regulatory board, National Medicinal Products Administration (NMPA) for Ciprocopan in treating patients with Paroxysmal N
- Zacks · Jul 8, 9:55 AM EDTWall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · Jul 1, 12:00 PM EDTWhat Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
- RTTNews · Jun 30, 12:30 AM EDTNuvectis Pharma Prices $100 Mln Offering Of Shares; Stock Down(RTTNews) – Nuvectis Pharma, Inc. (NVCT), a clinical-stage biopharmaceutical company, priced an offering of 5 million shares at $20.00 per share, with expected gross proceeds of $100 million.The offering is expected to close on or about July 1, 2026.
- Zacks · Jun 26, 12:00 PM EDTWhat Makes Nuvectis Pharma (NVCT) a New Buy StockNuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · Jun 24, 11:47 PM EDTTop Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High(RTTNews) – Today's top gainers include Pulsenmore, which has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the United States; IceCure Medical, whose ProSense technology was validated in an article published in the International
- RTTNews · Jun 22, 11:10 PM EDTTop Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLA(RTTNews) – Monday's top gainers include Tenon, following a Form S-1 filing; Azitra, which recently outlined its strategic reorientation and 2026 outlook; Nuvectis, after announcing a licensing deal with Haisco; and REGENXBIO, which is gearing up to resubmit its BLA for its Hunte
- RTTNews · Jun 20, 6:13 AM EDT5 Biotech Stocks That Delivered Triple-Digit Gains – SYRE Up 400%, BFLY Up 300% & More(RTTNews) – As renowned American investor Peter Lynch once said, "Know what you own, and know why you own it." This timeless principle remains one of the cornerstones of successful investing.
- Zacks · May 25, 9:55 AM EDTWall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a BetThe mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Nuvectis Pharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.